Bacterial infection in coronavirus disease 2019 patients: co-infection, super-infection and how it impacts on antimicrobial use

Wagner Nedel\textsuperscript{a,b}, Fernando da Silveira\textsuperscript{b,c}, Cristofer Farias da Silva\textsuperscript{a,c} and Thiago Lisboa\textsuperscript{a,c,d,e}

**Purpose of review**
Since the beginning of the severe acute respiratory syndrome coronavirus 2 pandemic, there has been a large increase in the consumption of antimicrobials, both as a form of treatment for viral pneumonia, which has been shown to be ineffective, and in the treatment of secondary infections that arise over the course of the severe presentation of coronavirus disease 2019 (COVID-19). This increase in consumption, often empirical, ends up causing an increase in the incidence of colonization and secondary infections by multi and pan-resistant germs.

**Recent findings**
The presence of a hyperinflammatory condition induced by the primary infection, associated with the structural damage caused by viral pneumonia and by the greater colonization by bacteria, generally multiresistant, are important risk factors for the acquisition of secondary infections in COVID-19. Consequently, there is an increased prevalence of secondary infections, associated with a higher consumption of antimicrobials and a significant increase in the incidence of infections by multi and pan-resistant bacteria.

**Summary**
Antimicrobial stewardship and improvement in diagnostic techniques, improving the accuracy of bacterial infection diagnosis, may impact the antibiotic consumption and the incidence of infections by resistant pathogens.

**Keywords**
coronavirus disease 2019, multidrug-resistant pathogens, nosocomial infection, pan-resistant pathogens, stewardship

**INTRODUCTION**
Bacterial co-infections and secondary infections identified in severe respiratory viral infections are associated with increased morbidity and mortality \cite{1}*. A relevant issue during the course of the coronavirus disease 2019 (COVID-19) pandemic is the real importance of co-infection in the presentation of the viral disease, since this circumstance can lead to an excessive use of antibiotics. Also, risk for bacterial superinfection during prolonged ICU and hospital stay in these patients also is associated with an increase in antimicrobial use in healthcare. In addition, use of antibiotics in the first wave (including azithromycin) as “specific” therapy, as well as an overestimation of risk for bacterial co-infection at hospital admission contribute to potential excessive use of antimicrobial in this setting. In this review, we discuss some of the studies assessing co-infection, superinfection and antimicrobial consumption during the pandemic period and its impact on outcomes.

**Pathophysiologica aspects**
Severe COVID-19 infection is associated, as well as others viral infections, with inflammatory response.
Pulmonary lesions in COVID-19 show pathological changes, degeneration, infiltration, and hyperplasia consistent with inflammatory response throughout the course of the disease [2]. A decrease in lymphocytes is characteristic of severe COVID-19, and this may be the major feature of COVID-19-induced immunosuppression [3]. On the other hand, the elevated level of inflammatory cytokines observed among patients with COVID-19 indicates an hyperinflammation state; and this paradoxical immunity status may complicate COVID-19 recovery [2,3]. The immune pathogenesis associated with an aberrant immune response result in lung damage, functional impairment, reduced pulmonary capacity and eventually death.

As a vital part of the adaptative immune system, lymphocytes play an important role in clearance of the invading virus and provide effective protection of human health under the virus threat [3]. Studies have shown that lymphopenia is a common feature in patients with COVID-19, with decreasing counts of CD4+ T cells, CD8+ T cells, and B cells [2–5]. The most significant decrease in these cell counts is associated with increased mortality in COVID-19 patients, with greater reductions in cell counts in severe COVID-19 patients [3]. Moreover, COVID-19 is associated with a diminished T-cell response [6] that are known to further slow down viral clearance, thus leading to a cytokine-driven vicious cycle [4].

The delayed type I interferon (IFN) response in coronavirus infections is known to be associated with more severe forms of the disease resulting in rapid viral multiplication and paradoxical hyperinflammation induced by type I interferons. Further activation of the type I IFN signaling pathways leads to a significant influx of neutrophils, inflammatory monocytes-macrophages, dendritic cells and natural killer (NK) cells into the lungs, potentiating lung damage [2,4]. Such cytokine liberation is associated with early acute respiratory distress syndrome (ARDS). Reduced levels of type 1 IFNs are associated with increased susceptibility to secondary bacterial infections [4]. Severe COVID-19 patients have higher cytokine levels (interleukin [IL]-6, IL-8, IL-2R, tumor necrosis factor alpha [TNF-α]) when compared with mild-to-moderate COVID-19 patients [2]. The hyper-inflammatory state eventually leads to a significant damage to the lung microvasculature and alveolar epithelium causing vascular leakage and alveolar edema resulting in life-threatening ARDS. These cytokines and chemokines have also been linked to extrapoluminal complications of COVID-19 including multiple-organ dysfunction syndrome.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may enhance colonization and attachment of bacteria to host tissue, and the combined infections may result in increased tissue destruction. Airway dysfunction, cytopathology and tissue destruction induced by SARS-CoV-2 infection or during bacterial co-infection may facilitate systemic dissemination of the virus and/or bacterial co-pathogens, dramatically increasing the risk of bloodstream infections and sepsis [4]. Changes in the bacterial composition of lower respiratory tract from patients with severe COVID-19, with a different bacterial diversity, composed multidrug-resistant bacteria such as Pseudomonas and Acinetobacter may be also a trigger for secondary infections [7].

ARDS per se is a trigger for immune impairment, which is associated with structural changes due to tissue damage and impaired mucociliary function, becoming a nidus for overlapping infections. Patients with ARDS typically demonstrate impaired immune response, including phagocytic function of alveolar neutrophils and prolonged suppression of immune function of macrophages and dendritic cells, and these variables may potentially reinforce immune dysfunction intrinsic to viral damage [8]. Figure 1 summarizes the main pathophysiological pathways that impair immune response in COVID-19 infection.

Is co-infection really an issue?

In another severe viral pneumonias, like influenza, bacterial co-pathogens are commonly identified in respiratory samples, and is associated with a greater severity of illness and increased risk of death [9]. In COVID-19, however, the spectrum is quite different. Despite the massive use of empirical antimicrobials on presentation, assuming a possible bacterial co-infection, the prevalence of this phenomenon is
relatively low, including severe COVID-19 presentations. Langford et al. [9], in a systematic review and meta-analysis of bacterial infection in severe COVID-19 patients, found a low prevalence (3.5%, 95% confidence interval [CI] 0.4–6.7%) of co-infection, most commonly *Mycoplasma*, *Haemophyllus* and *Pseudomonas* species. These findings were reinforced by a subsequent European multicenter study, analyzing early bacterial identification among intubated patients, the prevalence of bacterial identification was significantly lower in patients with SARS-CoV-2 pneumonia compared with patients with influenza pneumonia (9.7 versus 33.6%, adjusted odds ratio 0.23; 95% CI 0.16–0.33) [10*], suggesting that a relatively frequent phenomenon in severe forms of influenza is not reflected in the same way in COVID-19. Despite that, antibiotic prescription at ICU admission is extremely frequent, between 88% and 94% in multicenter cohorts [10*,11].

**Risk for secondary infections/healthcare-associated infection**

Secondary infections are the most important link between severe COVID-19 and bacterial infections. Virus pneumonia and secondary infection act as mutually reinforcing factors to promote the progression of COVID-19 [5]. These are the infectious complications most responsible for the increase in antimicrobial consumption in this population, frequently with the use of more than one antimicrobial class at the same time [1**].

The incidence of ventilator-associated pneumonia (VAP) is substantially higher in late phases of COVID-19 disease, due to the high rate of patients in ICU requiring invasive mechanical ventilation (MV), the long period of MV that these patients require, the need for prolonged infusions of sedative and neuromuscular blockers in this population [11,12] and the higher incidence of ARDS in this population, a well known risk factor for VAP [13]. VAP range from 21% to 64% of patients requiring MV, with a density ranging from 18 to 45 episodes per 1000 ventilator-days [14]. In a recent meta-analysis, a high proportion of COVID-19 patients treated with MV had VAP (45%), with a high mortality (42%) and a high mean ICU length of stay: 28 days (95% CI 21–35) [15*]. COVID-19 patients are significantly more likely to develop VAP than patients without COVID (hazard ratio 1.7–2.0) [12,13], with a higher incidence density when compared mechanically-ventilated patients without COVID-19 [12], and even when compared those with severe influenza infection [13].

The incidence of bloodstream infection (BSI) is high (10.3 BSI per 1000 patient-days), with a significant proportion of patients developing this complication, majorly during ICU stay [16], and more frequently of unknown source [17]. BSIs are also more frequent in COVID-19 patients than non-COVID patients [17]. Major risk factors for BSI are higher SAPS II, longer time from hospital to ICU admission, intubation during period at risk for BSI, renal replacement therapy, antibiotic use prior to BSI [16] and immunosuppressive drugs [17]. Patients with BSI have worse outcomes than patients without BSI, with longer ICU and hospital length of stay and higher mortality rate [16,17].

**Bacterial infections in coronavirus disease 2019 patients**

The most frequent pathogens isolated in different samples of COVID-19 co-infected patients are coagulase-negative *Staphylococcus* (CNS) species (60–70% of samples) [18] and *S. aureus* (25–45% of samples) [19,20].

In large multicentric studies, *S. aureus* frequently is the most frequently identified in sputum and among deep respiratory samples, causing lower respiratory co-infections [21], and the early bacterial identification in critically-ill COVID-19 patients is due to Gram-positive cocci (58,2%), mostly *S. aureus* and *S. pneumoniae* [22,23].

Among hospitalized patients with positive blood cultures, COVID-19 patients had a significantly higher proportion of cultures that likely represented contamination with normal skin microbiota than
non-COVID-19 patients. In this context, coagulase-negative *Staphylococcus* species accounted for 59.7% of all positive cultures among COVID-19 patients in contrast to 32.0% among patients that tested negative for SARS-CoV-2. The great challenge, in this context, is to differentiate contaminating pathogens in blood culture from those that are truly pathogenic to the host, and this is very clearly reflected in patients with COVID-19. When potential contaminants were excluded, the rate of bacteremia for COVID-19 patients decreased to 1.6%, which was significantly lower than the rate of bacteremia, excluding contaminants, among COVID-19-negative patients [18].

Similarly, the prevalence of Gram-negative germs are quite variable in the literature. Series that include nosocomial infection in their analysis, as well as non-respiratory foci (urinary, abdominal), have a higher prevalence of Gram-negative pathogens. Co-infection in early stages of disease is infrequent, but there is an increase in incidence at late stages [24,25]. The most commonly pathogen identified is *Enterobacteriales*, but nonfermenting Gram-negative bacilli were also very frequent [25]. Gram-negative is a common cause of secondary lower respiratory tract infections, and, in a large cohort, the most prevalent pathogens are *E. coli*, *K. pneumoniae* and *P. aeruginosa*, that is the most frequently isolated in those with chronic lung disease [21]. These pathogens are highly prevalent in other cohort [23], both in hospital-acquired pneumonia as well as ventilator-associated pneumonia. In series with high incidence of secondary infections due to *Klebsiella*, *Acinetobacter* and *Stenotrophomonas* species, there is an increase in rates of multidrug antimicrobial resistance, especially in carbapenem-resistant samples [25].

An ancillary analysis of the COVID-19 ICU study found first episode of BSI occurred after a median [IQR] of 9 [5–9,10*,12,13] days after hospital admission, and after adjusting for potential confounders using Cox model multivariable analysis, BSI occurring during hospital stay remained associated with day-90 mortality (hazard ratio [HR] 1.28, 95% CI 1.05–1.56) [26]. The incidence of bloodstream infection rises during the hospital stay; and there is a shift towards a higher prevalence of Gram-negatives and yeasts at this time [27], despite the major predominance of Gram-positives, particularly CNS, in distinct series [24]. The vast majority of blood samples become positive within 1–2 days of incubation, and among COVID-19 patients, 97.3% of positive cultures signaled positive within 3 days of incubation [18].

Hospital-acquired infections (HAs) are common in critically-ill COVID-19 patients, and the first episode commonly occurs in later stages of disease, in a median of 12 days according to one cohort study [28]. Ventilator-associated pneumonia is frequently the most common infection, followed by bloodstream infections. The majority of VAP episodes were caused by Gram-negative bacteria, and HAs secondary to multidrug-resistant bacteria, both Gram-positive (methicillin-resistant *S. aureus*) and Gram-negative (extended-spectrum beta-lactamase and carbapenemases). HAs prolong mechanical ventilation and hospitalization, and HAs complicated by septic shock showed an almost doubled mortality rate [28]. Descriptive findings in the most relevant cohorts are summarized in Table 1.

### Impact on antimicrobial consumption and stewardship policies

COVID-19 pandemic brought to light the discussion about the use of distinct antiinfective agents against viral infection. This discussion was based on some issues: the use of antimicrobials with in vitro activity against SARS-CoV-2, without evidence of in vivo activity [29–33], a difficulty in clinically differentiating bacterial and viral infection, and the presence of viral plus bacterial co-infection.

The advance of the pandemic resulted in overwhelmed health services globally and boosted the research for the magic bullet, which would help in the treatment of COVID-19. The lack of technical information for the management of patients affected by SARS-CoV-2 impacted the use and consumption of many drugs, mainly on antiinfective agents, with no scientific support based on evidence [33,34*].

Azithromycin, hydroxychloroquine and ivermectin showed in vitro activity against the SARS-CoV-2, and their widespread use generated an increase in the consumption of these drugs [34*]. Some clinical trials, such as RECOVERY and PETAL, were designed to assess the clinical benefit of hydroxychloroquine with or without azithromycin in hospitalized patients [35,36]. The results of these studies did not identify evidence of clinical benefit of hydroxychloroquine and/or azithromycin when compared to the usual standard of care, therefore, their use to treat COVID-19 is not recommended [35,36]. Ivermectin is another drug with in vitro activity that has been used against SARS-CoV-2. Although there are some clinical studies evaluating the use of ivermectin for the treatment of COVID-19, to date there are no adequate studies demonstrating clinical efficacy in this use.

Further issues which impacted antibiotics use were difficulties with viral and bacterial etiology differential diagnosis and the possibility of co-infection [37]. As previously mentioned in this review, there are many similarities between viral and bacterial infection signs. This fact justifies an initial antibiotic use, but when the pathogen...
causing the infection is identified, the antibiotic adjustment, de-escalation or interruption is mandatory, as advocated by rational antimicrobial use policies. Data about co-infection has demonstrated a low frequency of this event in noncritical inpatients, being unnecessary an antimicrobial coverage [9]. On the other hand, critical patients showed higher rates of bacterial and fungal co-infections, and the administration of broad-spectrum antimicrobial therapy is recommended in severe infections [38]. Despite a lack of evidence for antimicrobial use, its prescription was abundant against COVID-19 suspected or confirmed [34*,39], resulting in increased consumption of several classes of antibiotics such as aminoglycosides, macrolides, carbapenems, cephalosporins, glycopeptides, beta-lactam plus beta-lactamase inhibitors and macrolides, with exception of prophylaxis cephalosporins (cefazolin/cefotixin) [39]. A recent systematic review by Abu-Rub et al. [40] has evaluated the use of antibiotics for patients with confirmed SARS-CoV-2 infection admitted to ICU settings. That review showed that most of the studies (69.2%) had a lack of bacterial co-infection although antibiotics have been prescribed for patients [40]. In another study, Silva et al. [34*] compared antimicrobial consumption in COVID-19 and non-COVID-19 dedicated clusters (ICU, emergency department, and clinical ward). All COVID-19 clusters showed higher rates of antimicrobial use than non-COVID-19. Patients admitted in ICU usually receive antimicrobials, but in the COVID-19 scenario an overuse has been observed in some studies [34*,41,42]. Of note, data about antimicrobial consumption are predominantly from the beginning of the pandemic.

In this turbulent period, antimicrobial stewardship practices and organization were greatly impacted. Infectious diseases physicians were moved to the front line of care, leaving their roles in Stewardship uncovered, corroborating for antibiotics misuse [43]. Nowadays, there is an impact of the high use of antimicrobials on bacterial resistance, due to the misuse of antimicrobials in the pandemic period and the high number of multidrug-resistant infections in this population [44].

So far, studies reinforce the lack of effectiveness of antibiotics to treat COVID-19 infection. Furthermore, Stewardship principles must be applied to the maintenance of correct use of antimicrobials and prevent multidrug-resistant organisms’ development [44].

| Study, year | Country | Number of patients | Prevalence of bacterial infection (%) | Site of infection | Main pathogens isolated | Severity score |
|------------|---------|--------------------|--------------------------------------|------------------|------------------------|----------------|
| Nori, 2020 | USA     | 4267               | 3.6%                                 | 2.1% respiratory | S. aureus 44%, P. aeruginosa 16%, Klebsiella spp. 10% | Charlson Comorbidity Index 2 |
| Li, 2020   | China   | 1495               | 6.8%                                 | 86% respiratory  | A. baumannii 35%, K. pneumoniae 30%, S. maltophilia 6% | Not reported   |
| Grasselli, Italy, 2021 | Italy | 774                | 46% - HAI                           | Respiratory 50%, BSI 34% | Gram-negative: 64% | SOFA score 4, SAPS II 37 |
| Massart, France, Switzerland, 2021 | France, Switzerland and Belgium | 4010               | 19%                                 | Enterobacteriaceae 14%, MSSA 9%, MRSA 3% | SOFA score 7, SAPS II 40 |
| Sepulveda, 2020 | USA | 28011              | 3.8%                                 | E. coli 16%, S. aureus 13%, Klebsiella 10% | Not reported |
| Ripa, 2021 | Italy   | 731                | 7.9% (BSI) and 3% (LRTI)             | BSI and respiratory | CNS 69%, 42% LRTI | Not reported |
| Garcia-Vidal, 2021 | Spain | 989                | 7.2%                                 | BSI, respiratory and urinary | S. pneumoniae 16%, S. aureus 16%, P. aeruginosa 13% | Not reported |
| Scott, 2021 | USA     | 1398               | 8%                                   | Respiratory      | S. aureus 25%, K. pneumoniae 14%, P. aeruginosa 12% | Charlson Comorbidity Index (mean) 0 |

BSI: bloodstream infection; LRTI, lower respiratory tract infection; SAPS: Simplified Acute Physiology Score; SOFA: Sequential Organ Failure Assessment.
Severe infections

CONCLUSION

Despite concerns regarding risk of co-infection in COVID-19 patients, secondary infections are the most important link between severe COVID-19 and bacterial infections. These HAI on outcomes such as mechanical ventilation and hospitalization duration, risk for complications such as shock and organ dysfunction and mortality. Unnecessary increased consumption of antimicrobial agents during pandemic, particularly at admission, might have impact on multidrug resistant pathogens emergence and difficult to treat health-care associated infections.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest

•• of outstanding interest

1. Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021; 2:e354–e365.

•• Relevant multicentric cohort study estimating incidence of co-infections in hospitalized patients with COVID-19, and exploring antimicrobial use in this population.

2. Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Investig 2021; 51:e13429.

••• Multicentric study demonstrating a lower incidence of co-infection in severely-ill COVID-19 patients during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42:84–88.

3. Scott H, Zahra A, Fernandes R, et al. Bacterial infections and death among patients with Covid-19 versus non-COVID-19 patients with pneumonia. Am J Emerg Med 2022; 51:1–5.

4. Russell CD, Fairfield CJ, Drake TM, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021; 2:e354–e365.

•• Relevance multicentric cohort study estimating incidence of co-infections in hospitalized patients with COVID-19 or influenza pneumonia: a European multicentre comparative clinical trial. Am J Respir Crit Care Med 2021; 204:546–556.

5. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. 2020.

6. Graselli B, Scaravilli V, Marrie T, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest 2021; 180:454–465.

7. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6:.

8. Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int J Antimicrob Agents 2020; 56:106020.

9. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog 2020; 145:104228.

10. Jans DA, Waspafst KM. The broad spectrum host-directed agent vermacin as an antiviral for SARS-CoV-2. Biodriven Biophys Res Commun 2021; 538:163–172.

11. Popp M, Stegemann M, Riemer M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev 2021; (7); Art. No CD015017.

12. da Silva CF, Deutschendorf C, Nagel FM, et al. Effect of the pandemic on antimicrobial consumption patterns. Infect Control Hosp Epidemiol 2021; 42:1170–1172. Observational study demonstrating the impact on antimicrobial consumption in patients with COVID-19, when compared to patients without the disease.

13. Rouzé A, Martin-Löeches I, Povoa P, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 2021; 47:188–198.

14. Fumagalli J, Panigada M, Klompas M, Berra L. Ventilator-associated pneumonia among SARS-CoV-2 acute respiratory distress syndrome patients. Crit Care 2022; 26:462.

15. Ippolito M, Misseri G, Catalisano G, et al. Ventilator-associated pneumonia in patients with COVID-19: a systematic review and meta-analysis. Antibiotics 2021; 10:545.

16. Study summarizing clinical outcomes of patients with COVID-19 who developed ventilator associated pneumonia. 2020.

17. Massart N, Maxime V, Fillatre P, et al. Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study. Ann Intensive Care 2021; 11:183.

18. Buetti N, Ruský D, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med 2021; 47:180–187.

19. Sepulveda J, Westblade LF, Whittier S, et al. Bacteremia and blood culture utilization during covid-19 surge in New York City. J Clin Microbiol 2020; 58: e00995-20.

20. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalised during the New York City pandemic surge. Infect Control Hosp Epidemiol 2021; 42:84–88.

21. Rouze A, Martin-Löeches I, Povoa P, et al. Early bacterial identification among intubated patients with COVID-19 or influenza pneumonia: a European multicenter comparative clinical trial. Am J Respir Crit Care Med 2021; 204:546–556.

22. Hughes S, Troise O, Donaldson H, et al. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. 2020.

23. Li J, Wang J, Yang Y, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control 2020; 9:153.

24. Li J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6:.

25. Rothe K, Feihl S, Schneider J, et al. Antiviral for SARS-CoV-2? Biochem Biophys Res Commun 2021; 9:1958–1964.

26. Buetti N, Ruský D, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med 2021; 47:180–187.

27. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. 2020.

28. Grasselli G, Scaravilli V, Marrie T, et al. Hospital-acquired infections in critically ill patients with COVID-19. Chest 2021; 180:454–465.

29. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6:.

30. Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int J Antimicrob Agents 2020; 56:106020.

31. Andreani J, Le Bideau M, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog 2020; 145:104228.

32. Jans DA, Waspafst KM. The broad spectrum host-directed agent vermacin as an antiviral for SARS-CoV-2. Biodriven Biophys Res Commun 2021; 538:163–172.

33. Popp M, Stegemann M, Riemer M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev 2021; (7); Art. No CD015017.

34. da Silva CF, Deutschendorf C, Nagel FM, et al. Impact of the pandemic on antimicrobial consumption patterns. Infect Control Hosp Epidemiol 2021; 42:1170–1172. Observational study demonstrating the impact on antimicrobial consumption in patients with COVID-19, when compared to patients without the disease.

35. Ablavese E, Abbas M, Abbas S, et al. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397:605–612.

36. Seif WH, Senter MK, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA 2020; 324:1170–1172.

37. Maastricht U, Chen M, Patner J, et al. Impact of rapid multiplex PCR on management of antibiotic therapy in COVID-19-positive patients hospitalized in intensive care unit. Eur J Clin Microbiol Infect Dis 2021; 40:2227–2234.

38. Rothe K, Feihl S, Schneider J, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis 2021; 40:859–869.
39. Castro-Lopes A, Correia S, Leal C, et al. Increase of antimicrobial consumption in a tertiary care hospital during the first phase of the COVID-19 pandemic. Antibiotics (Basel) 2021; 10:.
40. Abu-Rub LI, Abdelrahman HA, Johar ARA, et al. Antibiotics prescribing in intensive care settings during the COVID-19 era: a systematic review. Antibiotics (Basel) 2021; 10:935.
41. Guisado-Gil AB, Harte-Dominguez C, Perelva G, et al. Impact of the COVID-19 pandemic on antimicrobial consumption and hospital-acquired candidemia and multidrug-resistant bloodstream infections. Antibiotics 2020; 9:1–11.
42. Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, et al. Evolution of antimicrobial consumption during the first wave of covid-19 pandemic. Antibiotics 2021; 10:1–10.
43. Magnasco L, Mikulska M, Giacobbe DR, et al. Spread of carbapenem-resistant gram-negatives and candida auris during the COVID-19 pandemic in critically ill patients: one step back in antimicrobial stewardship? Microorganisms 2021; 9:1–10.
44. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect 2021; 27:9–11.